Spyre Therapeutics (NASDAQ: SYRE) Soars on Positive Phase 2 Ulcerative Colitis Trial Results

  • Spyre Therapeutics (NASDAQ: SYRE) announced successful Phase 2 SKYLINE trial results for its drug candidate SPY001, targeting moderate-to-severe ulcerative colitis.
  • The trial achieved its primary goal with a statistically significant 9.2-point reduction in the Robart's Histopathology Index (RHI) score, alongside key secondary goals including 40% clinical remission.
  • Deutsche Bank raised its price target for Spyre Therapeutics to $88.00, indicating a potential 39.09% upside, which contributed to a 23.36% single-day stock surge and a market capitalization of approximately $3.82 billion.

Spyre Therapeutics (NASDAQ: SYRE) is a biotechnology company developing treatments for inflammatory bowel disease. The company is currently focused on its drug candidate, SPY001, which is being tested as a potential treatment for moderate-to-severe ulcerative colitis, a chronic inflammatory condition affecting the large intestine.

Following positive trial results, Deutsche Bank raises its price target on Spyre Therapeutics to $88.00, a significant increase from its previous target of $55.00. This new target suggests a potential upside of approximately 39.09% from the stock's price of $63.27 at the time of the announcement.

The analyst's confidence comes after Spyre Therapeutics announced successful results from its Phase 2 SKYLINE trial. As highlighted by GlobeNewswire, the trial met its primary goal. It showed a statistically significant 9.2-point reduction in the Robart's Histopathology Index (RHI) score, a measure of disease activity, at week 12.

The trial also achieved key secondary goals, with 40% of patients reaching clinical remission and 51% showing endoscopic improvement. Benzinga highlights that this positive data has caused the stock to trade higher. The company reports that SPY001 was well-tolerated by patients during the study.

The market has reacted strongly to the news. The stock's price has risen by 23.36% in a single day, reaching a new 52-week high of $75.00. The company's market capitalization, which is the total value of all its shares, now stands at approximately $3.82 billion.

About the Author
Rayan Ahmad

Market news and analyst rating coverage

Rayan Ahmad covers market news, analyst rating changes, and company developments for the FMP blog. His work focuses on summarizing price-target updates, earnings results, and broker actions into accessible, data-backed market updates.

Related

Financial data for every need

Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions — all accessible via API.

Create Free Account